E-DRUG: Medicines & Markets - the role of Pharmaceuticals in Global Health Policy
---------------------------------------------------------------------------------------------------
Dear e-drug readers
This information kindly copied from HSG blog could interest some of you.
Best regards
Etienne
Medicines & Markets - the role of Pharmaceuticals in Global Health Policy
*By Giuliano Russo <http://www.ihmt.unl.pt/en/profiles/giuliano-russo/>\-
member of the Medicines in Health Systems Thematic Working Group
<http://www.healthsystemsglobal.org/twg-group/7/Medicines-in-Health-Systems/>
and Stefan
Elbe <http://www.sussex.ac.uk/profiles/174796>\- Director of the Centre for
Global Health Policy, University of Sussex*
Pharmaceuticals are pivotal to global health policy. Outbreaks of pandemic
flu, Ebola, MERS and now Zika are intensifying international efforts to
streamline pharmaceutical development
<http://www.sciencedirect.com/science/article/pii/S0277953614002664>\.
Concern about global health security threats - from the rise of
anti-microbial resistance
<http://steps-centre.org/wp-content/uploads/AMR.pdf>
to the spectre of a bio-terrorist attack - are fanning bespoke pharmaceutical regimes for the development, manufacture and distribution of innovative medical
countermeasures
<http://www.ids.ac.uk/publication/global-governance-and-the-limits-of-health-security>
At the same time, a number of influential global health actors are working
tirelessly to narrow the pharmaceutical gap between high- and low-income
countries, with the aim of making many life-saving pharmaceuticals more
accessible in low-income countries. They also hope to encourage the
development of more innovative medicines to treat neglected diseases for
which there is no underlying commercial market
<http://www.elgaronline.com/view/9781849800143.xml>\.
These developments are underpinned by the emergence of new manufacturing capabilities in many low- and middle-income countries - with the potential to reshape the global political economy of pharmaceuticals production and consumption
<http://www.palgrave.com/us/book/9781137546463> in the decades ahead.
On June 9th the Instituto de Higiene e Medicina Tropical of Lisbon
and the Centre for Global Health Policy at the University of Sussex
will be hosting a workshop on - Pharmaceuticals and Global Health Policy
The event brings together a number of researchers analysing different
dimensions of the role played by pharmaceuticals in contemporary global
health policy – from medicines and medical countermeasures, through to
markets and manufacturers.
Across four panels and 12 presentations, UK and international experts will
present and discuss ongoing research work on Pharmaceuticals and Global Health Security, The Global Supply of Medicines;
The Political Economy of Developing Local Health Technology Capacity, and;
Addressing Anti-microbial resistance in Pluralistic Human and Animal Health
Systems. Researchers from both the Medicines in Health Systems
and the Private Sector in Health
<http://www.healthsystemsglobal.org/twg-group/3/The-Private-Sector-in-Health/>
Thematic Working Groups will be presenting at the event.
The workshop aims to;
(a) facilitate interdisciplinary, social science
dialogue across a number of distinct research projects focusing on
pharmaceuticals in global health policy;
(b) enabling researchers to showcase their work in this area to cognate researchers – comparing commonalities and tensions across different areas of global health policy,
and;
(c) exploring the scope and avenues for possible future collaboration.
Some of the overarching questions of the workshop will include:
- What are the main drivers behind the proliferation of pharmaceutical
logics and solutions in contemporary global health policy?
- How do multi-national pharmaceutical companies balance their commercial
needs with the more humanitarian imperatives of global health?
- What role do global governance structures – from formal institutions to
legal regimes and intellectual property – play in these dynamics?
- What role do markets and manufacturers from low- and middle-income
countries play in these processes?
- What are the obstacles and resistances to approaching global health
problems pharmaceutically?
- Is the pharmaceuticalization of global health policy sustainable?
Find out more
More information on the event
<http://www.sussex.ac.uk/globalhealthpolicy/%20events/workshops/pharmaceuticalsandglobalhealthpolicy>
We will be writing a blog picking up on some of the out some of the key
discussion points after the event, which will appear here on the HSG blogs
page.
Etienne Guillard - PharmD, MSc
Health Systems & Services Strengthening Director
Solthis - www.solthis.org
Etienne Guillard <etienne.guillard@gmail.com>